BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 7, 2005
View Archived Issues
With Flurizan In Phase III, Myriad Bringing In $130M
As lead product Flurizan is being tested in a Phase III trial for Alzheimer's disease, Myriad Genetics Inc. priced a public offering of its common stock to raise $129.5 million. (BioWorld Today)
Read More
Introgen Agrees To $20M Partnership With Colgate
Read More
Cytori Forms $55M Stem Cell Joint Venture With Olympus
Read More
FDA Panel Backs Idea Of HIV Tests Being Sold OTC
Read More
Vernalis Paying Mylan $23M For U.S. Rights To Apokyn
Read More
Array Partners With Ono For Drug Discovery Work
Read More
Other News To Note
Read More